ClinicalTrials.gg
CompletedNCT02613221APOLLONUpdated Jul 31, 2019Results posted

A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer

A Phase 1/2 interventional study of Panitumumab + TAS-102 in Colorectal Cancer, sponsored by Takeda. Completed at 32 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2019-07-31.

Sponsored by Takeda · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
50th of 88
56 · median 70
Started
2015
with 4 others
Phase 1/2
7 of 90
none open now
Registered
63rd of 90
by date
Lead sponsor
3 of 90
Takeda

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 50th largest by enrollment of the 88 interventional ones that give a count, is one of 5 that started in 2015, is one of 7 in phase 1/2, and was the 63rd registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the combination of panitumumab and Triflridine/Tipiracil (FTD/TPI; TAS-102) in patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard chemotherapy (oxaliplatin, fluoropyrimidines, irinotecan and angiogenesis inhibitors).

Read the detailed description

The purpose of this study is to evaluate the combination of panitumumab and TAS-102 in patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard chemotherapy (oxaliplatin, fluoropyrimidines, irinotecan and angiogenesis inhibitors).

Patients who are judged eligible for the study based on the inclusion and exclusion criteria will be received panitumumab (6 mg/kg) every 2 weeks and TAS-102 (35 mg/m² given orally twice a day in a 28-day) in 2-week cycle of 5 days of treatment followed by a 2-day rest period, and then a 14-day rest period.

A maximum of 58 participants will be enrolled.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Metastatic colorectal cancer, Panitumumab, TAS-102
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Investigator and subinvestigator judge a candidate is understand clinical trial and comply this protocol.
  2. Participants who have given written consent to take part in the study after detailed explanation of the study prior to enrollment
  3. Aged ≥20 to \<75 years at the time of
  4. Participants with unresectable adenocarcinoma originating in the large intestine (excluding carcinoma of the appendix and anal canal cancer)
  5. Participants with lesion(s) that can be evaluated. It is essential to be evaluated the tumor according to the (RECIST) ver. 1.1.
  6. Participants who have received chemotherapies for colorectal cancer and are to or failing those chemotherapies* including; fluoropyrimidines, irinotecan, oxaliplatin, and an angiogenesis inhibitors.

    *: Refractory to or failing those chemotherapies are defied as following;

    • If recurrence is observed by imaging during /adjuvant therapy, or within 6 months of the completion of adjuvant therapy.
    • If imaging or clinical progression is observed during or within 3 months of the last dose of chemotherapy for advanced cancer.
    • When it is determined that the drugs (ie, fluropyrimidines, oxaliplatin, irinotecan, and angiogenesis inhibitors) are not allowed to be resume due to intolerable AE toxicities (eg, serious allergic reaction and accumulative neuropathy).
  7. Participants classified as KRAS/NRAS wild-type** by KRAS/NRAS testing*.

    *: KRAS/NRAS test will be performed using the in vitro diagnostic listed in the National Health Insurance.

    **: Participants with no mutation in any of the codons shown below are considered wild type.

    KRAS: EXON2 (codon 12, 13), EXON3 (codon 59, 61), EXON4 (codon 117, 146) NRAS:EXON2 (codon 12, 13), EXON3 (codon 59, 61),EXON4 (codon 117, 146)

  8. Participants are able to take medications orally.
  9. Participants who satisfy the following criteria for the major organ function in tests performed within 14 days prior to enrollment

    • ≥1.5×10\^3/µL
    • count ≥1.0×10\^4/µL
    • ≥8.0 g/dL
    • Total ≤1.5 mg/dL
    • (AST) ≤ 100 IU/L ( ≤200 IU/L if liver metastases are present)
    • Alanine aminotransferase (ALT) ≤ 100 IU/L ( ≤200 IU/L if liver metastases are present)
    • Serum creatinine ≤ 1.5 mg/dL
  10. (ECOG) performance status (PS) of 0 or 1
  11. of ≥ 3 months (90 days) after enrollment

Exclusion criteria

Exclusion Criteria:

  1. Has received anti-EGFR antibodies (cetuximab or panitumumab), regorafenib, or TAS-102.
  2. Has had treatment with radiotherapy and/or chemotherapy within 2 weeks (14 days) prior to study drug administration (except for limited field radiation in order to rescue of pain).
  3. Known or strongly suspected of brain metastasis
  4. Synchronous cancers or metachronous cancers with a disease-free period of ≥ 5 years (excluding colorectal cancer) excluding mucosal cancers cured or be possibly cured by regional resection (esophageal, stomach, and cervical cancer, non-melanoma skin cancer, bladder cancer, etc.).
  5. Body cavity fluid that requires treatment (pleural effusion, ascites, pericardial effusion, etc.)
  6. Participants who do not want to use to prevent pregnancy, and women who are pregnant or breast-feeding, or test positive for pregnancy
  7. Any agent received within prior 4 weeks (28 days).
  8. Disease requiring systemic for treatment (excluding topical steroids)
  9. History or obvious and extensive CT findings of interstitial pulmonary disease (interstitial pneumonia, pulmonary fibrosis, etc.)
  10. Intestinal paralysis, gastrointestinal obstruction, or uncontrollable diarrhea (incapacitating symptoms despite adequate treatment.
  11. Serious drug (without allergy to oxaliplatin)
  12. Local or systemic active infection requiring treatment, or fever indicating infection
  13. class II or higher heart failure or serious heart disease
  14. Active
  15. Known infection
  16. Adverse event due to previous treatment that has not recovered to Grade 1 (Grade 2 for peripheral sensory neuropathy) by (Japanese edition JCOG version 4.03) (excluding content)
  17. Known BRAF mutation
  18. Other participants judged by the investigator or subinvestigator to be ineligible for enrollment in the study (such as patients who were coerced to give consent)
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    panitumumab + TAS-102 combination therapy

    Panitumumab 6 mg/kg every 2 weeks, plus TAS-102 35 mg/m² given orally twice a day in 5 days followed by a 2-day rest period for 2-week cycle, and then a 14-day rest period (28 days per 1 course).

    Drug: Panitumumab + TAS-102

Interventions

  • DrugPanitumumab + TAS-102

    Drug page: Panitumumab

    panitumumab + TAS-102 combination therapy

    Also known as: Panitumumab + Triflridine/Tipiracil (FTD/TPI)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicity (DLT) With Panitumumab Plus TAS-102 Combination Therapy

    DLT was evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 and was defined as any of the following events: 1. Grade 4 neutropenia for more than 7 days under maximum supportive therapy; 2. Febrile neutropenia; 3. Platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; 4. If Course 2 was not initiated within 14 days due to AE related to the protocol treatment; 5. Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except the following cases, Grade 3 gastrointestinal symptoms that could be controlled with supportive therapy (eg, appropriate use of antiemetics, antidiarrheals), and Grade 3 or higher electrolyte abnormalities that were not deemed clinically significant.

    Time frame: Up to approximately 1 month

  2. Progression Free Survival (PFS) Rate at 6 Months

    PFS rate at 6 months was defined as the crude rate of surviving participants who survived or were not determined as progressive at 6 months from the day of enrollment. Although the subjects who had no imaging data on progression at 6 months after enrollment or the subjects who had lost to follow-up were included in the denominator, these subjects were not handled as progression-free. Progression included both progression disease (PD) based on diagnostic imaging assessed according to response evaluation criteria in solid tumors (RECIST) ver 1.1 and primary disease progression that cannot be confirmed by diagnostic imaging (clinical progression). PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

    Time frame: Up to 6 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the period from the day of enrollment until death by all causes.

    Time frame: From date of enrollment until the death, assessed up to approximately 29 months

  2. Progression Free Survival (PFS)

    PFS was defined as the period from the day of enrollment until the day of documented progression or the day of death due to all causes whichever comes earlier. Progression included both PD based on diagnostic imaging assessed according to response evaluation criteria in solid tumors (RECIST) ver 1.1 and primary disease progression that cannot be confirmed by diagnostic imaging (clinical progression). PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

    Time frame: From date of enrollment until the date of progression or death, assessed up to approximately 29 months

  3. Response Rate (RR)

    RR was defined as the percentage of participants who had shown complete response (CR) or partial response (PR) as the best overall response in accordance with the RECIST 1.1 criteria. The best overall response was CR, followed by PR, stable disease (SD), progressive disease (PD), and not evaluable (NE). CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters as the best overall response after randomization., SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

    Time frame: From date of enrollment until the end of follow-up period, assessed up to approximately 29 months

  4. Duration of Response (DOR)

    DOR means that the period from the day when either CR or PR is first confirmed until the day of documented PD or the day of death due to all causes, whichever occurs earlier.

    Time frame: From date of CR or PR until the date of PD or death, assessed up to approximately 29 months

  5. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants who had shown CR, PR, or SD as the best overall response in accordance with the RECIST version 1.1 criteria.

    Time frame: From date of enrollment until the end of follow-up period, assessed up to approximately 29 months

  6. Time to Treatment Failure (TTF)

    TTF was defined as the time from the date of enrollment to the date of the decision to discontinue the protocol treatment, the date of documented progression during the protocol treatment, or the date of death from any cause, whichever had come earlier.

    Time frame: From date of enrollment until the date of the protocol treatment discontinuation, progression or death, assessed up to approximately 29 months

  7. Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs)

    Adverse events (AEs) were any unfavorable medical events encountered in a participant treated with a drug. They were not limited to the events with clear causal relationship with treatment with the concerned drug. Treatment-emergent adverse events (TEAEs) were defined as AEs that had occurred after the initiation of protocol treatment.

    Time frame: From first dose of the study drug through 30 days after the last dose of study drug or start of subsequent antineoplastic therapy, assessed up to approximately 29 months

07

Results

Posted Jun 24, 2019

Participant flow

Participants took part in the study at 25 investigative sites in Japan, from 08 December 2015 to 30 March 2018.

Participant flow — Overall Study
MilestonePanitumumab + TAS-102
Started56
Safety population: received study drug55
Completed1
Not completed55
Withdrew: Lack of efficacy (exacerbation)50
Withdrew: Adverse event2
Withdrew: Voluntary discontinuation1
Withdrew: Delayed treatment1
Withdrew: Enrolled but not treated1

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicity (DLT) With Panitumumab Plus TAS-102 Combination Therapy

DLT was evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 and was defined as any of the following events: 1. Grade 4 neutropenia for more than 7 days under maximum supportive therapy; 2. Febrile neutropenia; 3. Platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; 4. If Course 2 was not initiated within 14 days due to AE related to the protocol treatment; 5. Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except the following cases, Grade 3 gastrointestinal symptoms that could be controlled with supportive therapy (eg, appropriate use of antiemetics, antidiarrheals), and Grade 3 or higher electrolyte abnormalities that were not deemed clinically significant.

Time frame:
Up to approximately 1 month
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicity (DLT) With Panitumumab Plus TAS-102 Combination Therapy
ParticipantsPanitumumab + TAS-102
Number of Participants With Dose Limiting Toxicity (DLT) With Panitumumab Plus TAS-102 Combination Therapy0
PrimaryProgression Free Survival (PFS) Rate at 6 Months

PFS rate at 6 months was defined as the crude rate of surviving participants who survived or were not determined as progressive at 6 months from the day of enrollment. Although the subjects who had no imaging data on progression at 6 months after enrollment or the subjects who had lost to follow-up were included in the denominator, these subjects were not handled as progression-free. Progression included both progression disease (PD) based on diagnostic imaging assessed according to response evaluation criteria in solid tumors (RECIST) ver 1.1 and primary disease progression that cannot be confirmed by diagnostic imaging (clinical progression). PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

Time frame:
Up to 6 months
Reported as:
Number · Percentage of Participants
Progression Free Survival (PFS) Rate at 6 Months
Percentage of ParticipantsPanitumumab + TAS-102
Progression Free Survival (PFS) Rate at 6 Months33.3 (22.77 to 45.32)
SecondaryOverall Survival (OS)

OS was defined as the period from the day of enrollment until death by all causes.

Time frame:
From date of enrollment until the death, assessed up to approximately 29 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPanitumumab + TAS-102
Overall Survival (OS)14.1 (12.18 to 19.29)
SecondaryProgression Free Survival (PFS)

PFS was defined as the period from the day of enrollment until the day of documented progression or the day of death due to all causes whichever comes earlier. Progression included both PD based on diagnostic imaging assessed according to response evaluation criteria in solid tumors (RECIST) ver 1.1 and primary disease progression that cannot be confirmed by diagnostic imaging (clinical progression). PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

Time frame:
From date of enrollment until the date of progression or death, assessed up to approximately 29 months
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsPanitumumab + TAS-102
Progression Free Survival (PFS)5.8 (4.46 to 6.50)
SecondaryResponse Rate (RR)

RR was defined as the percentage of participants who had shown complete response (CR) or partial response (PR) as the best overall response in accordance with the RECIST 1.1 criteria. The best overall response was CR, followed by PR, stable disease (SD), progressive disease (PD), and not evaluable (NE). CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters as the best overall response after randomization., SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

Time frame:
From date of enrollment until the end of follow-up period, assessed up to approximately 29 months
Reported as:
Number · Percentage of Participants
Response Rate (RR)
Percentage of ParticipantsPanitumumab + TAS-102
Response Rate (RR)37.0 (24.29 to 51.26)
SecondaryDuration of Response (DOR)

DOR means that the period from the day when either CR or PR is first confirmed until the day of documented PD or the day of death due to all causes, whichever occurs earlier.

Time frame:
From date of CR or PR until the date of PD or death, assessed up to approximately 29 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsPanitumumab + TAS-102
Duration of Response (DOR)4.1 (2.29 to 6.29)
SecondaryDisease Control Rate (DCR)

DCR was defined as the percentage of participants who had shown CR, PR, or SD as the best overall response in accordance with the RECIST version 1.1 criteria.

Time frame:
From date of enrollment until the end of follow-up period, assessed up to approximately 29 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR)
Percentage of ParticipantsPanitumumab + TAS-102
Disease Control Rate (DCR)81.5 (68.57 to 90.75)
SecondaryTime to Treatment Failure (TTF)

TTF was defined as the time from the date of enrollment to the date of the decision to discontinue the protocol treatment, the date of documented progression during the protocol treatment, or the date of death from any cause, whichever had come earlier.

Time frame:
From date of enrollment until the date of the protocol treatment discontinuation, progression or death, assessed up to approximately 29 months
Reported as:
Median · Months
Time to Treatment Failure (TTF)
MonthsPanitumumab + TAS-102
Time to Treatment Failure (TTF)5.8 (4.29 to 6.21)
SecondaryNumber of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs)

Adverse events (AEs) were any unfavorable medical events encountered in a participant treated with a drug. They were not limited to the events with clear causal relationship with treatment with the concerned drug. Treatment-emergent adverse events (TEAEs) were defined as AEs that had occurred after the initiation of protocol treatment.

Time frame:
From first dose of the study drug through 30 days after the last dose of study drug or start of subsequent antineoplastic therapy, assessed up to approximately 29 months
Reported as:
Count of participants · Participants
Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPanitumumab + TAS-102
Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs)55

Adverse events

Collected over From first dose of the study drug through 30 days after the last dose of study drug or start of subsequent antineoplastic therapy, assessed up to approximately 29 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab + TAS-1026/55 (10.9%)13/55 (23.6%)54/55 (98.2%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPanitumumab + TAS-102
Febrile neutropeniaBlood and lymphatic system disorders5/55
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/55
AnaemiaBlood and lymphatic system disorders1/55
VomitingGastrointestinal disorders1/55
General physical health deteriorationGeneral disorders1/55
PyelonephritisInfections and infestations1/55
Infusion related reactionInjury, poisoning and procedural complications1/55
Metastases to spineNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/55
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/55
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/55
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPanitumumab + TAS-102
StomatitisGastrointestinal disorders39/55
Neutrophil count decreasedInvestigations36/55
Dermatitis acneiformSkin and subcutaneous tissue disorders34/55
Decreased appetiteMetabolism and nutrition disorders30/55
FatigueGeneral disorders27/55
Dry skinSkin and subcutaneous tissue disorders27/55
NauseaGastrointestinal disorders23/55
ParonychiaInfections and infestations23/55
DiarrhoeaGastrointestinal disorders17/55
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders14/55

Baseline characteristics

Safety Analysis Set, The safety analysis set was defined as all participants who received at least one dose of the study drug during the study.

Age, Continuous
Age, Continuous(Years)Panitumumab + TAS-102
Mean59.5 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab + TAS-102
Female26
Male29
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Panitumumab + TAS-102
Region of Enrollment
Region of Enrollment(Participants)Panitumumab + TAS-102
Japan55
Height
Height(Centimeters (cm))Panitumumab + TAS-102
Mean162.5 ± 9.2
Weight
Weight(kilograms (kg))Panitumumab + TAS-102
Mean62.66 ± 14.67
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Panitumumab + TAS-102
Mean23.57 ± 4.39
Duration of First-line Treatment
Duration of First-line Treatment(Days)Panitumumab + TAS-102
Median595.5 (72 to 2240)

9 further baseline measures are reported on the registry.

08

Study locations

32 sites
  • Nagoya, Aichi, Japan
  • Kashiwa, Chiba, Japan
  • Matsuyama, Ehime, Japan
  • Kitakyushu, Fukuoka, Japan
  • Kurume, Fukuoka, Japan
  • Hakodate, Hokkaido, Japan
  • Kushiro, Hokkaido, Japan
  • Sapporo, Hokkaido, Japan
  • Amagasaki, Hyogo, Japan
  • Kobe, Hyogo, Japan
  • Tsukuba, Ibaragi, Japan
  • Kasama, Ibaraki, Japan
  • Miki, Kagawa, Japan
  • Sagamihara, Kanagawa, Japan
  • Osaki, Miyagi, Japan
  • Matsumoto, Nagano, Japan
  • Sasebo, Nagasaki, Japan
  • Yamatotakada, Nara, Japan
  • Takatsuki, Osaka, Japan
  • Ina, Saitama, Japan
  • Shizuoka, Shizioka, Japan
  • Nagaizumi, Shizuoka, Japan
  • Koto-ku, Tokyo, Japan
  • Minato-ku, Tokyo, Japan
  • Chiba, Japan
  • Fukui, Japan
  • Fukuoka, Japan
  • Kumamoto, Japan
  • Okayama, Japan
  • Okinawa, Japan
  • Osaka, Japan
  • Toyama, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Oct 2017, 21 months.

Results were first posted in Jun 2019, 1 year 8 months after primary completion.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's 21 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2015
First posted
Nov 24, 2015
StartActual
Dec 7, 2015
Primary completionActual
Oct 6, 2017
CompletionActual
Mar 30, 2018
Results first posted
Jun 24, 2019
Last update
Jul 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02613221
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 24, 2015
Start date
Dec 7, 2015
Primary completion
Oct 6, 2017
Completion
Mar 30, 2018
Results posted
Jun 24, 2019
Last update
Jul 31, 2019

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion